Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

COMPASSHER2

99 years and younger
All genders
CompassHER2 RD (A011801) is a randomized trial in patients with residual disease after a predefined course of neoadjuvant HER2-directed treatment.
Learn More

NRG-BR009

99 years and younger
All genders
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence …
Learn More

LGH 2022-29: Novartis Kymriah MAP

99 years and younger
All genders
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. The primary purpose of a MAP is to provide access to product. NA - …
Learn More

LGH 2024-03: MajesTEC-9

99 years and younger
All genders
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.
Learn More

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (IMGN151)

18-99 years
All genders
To assess safety and tolerability, including dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), or maximum administered dose (MAD; if no MTD is defined) of IMGN151 when administered intravenously To determine recommended Phase 2 dose (RP2D) for IMGN151 To characterize the pharmacokinetics (PK) and immunogenicity of IMGN151 -To assess ORR for …
Learn More

BHB-T cells

18-99 years
Accepts healthy volunteer
All genders
The aim of this study is to biobank blood and stool samples of healthy individuals receiving β-hydroxybutyrate (BHB) supplementation. Additionally, this study will determine whether BHB supplementation increases serum BHB levels and leads to changes in T cell phenotype, including composition (i.e. CD4/CD8), and cytokine secretion. BHB supplementation will be …
Learn More

Variability in analgesic response to ibuprofen

99 years and younger
All genders
The objectives of the study are:To investigate demographic, clinical, genetic, and environmental factors that contribute to variability in analgesic response to ibuprofen.To compare the inflammatory profile and neutrophil phenotypes between patients who use supplemental opioids and those who do not.To establish a well-phenotyped cohort of subjects, with biobanked samples, that …
Learn More

LGH 2023-38: A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

99 years and younger
All genders
Investigate the efficacy and safety of luveltamab tazevibulin compared to IC chemotherapy in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting FOLR1 which is expressed in approximately 80% of recurrent ovarian cancers, and expression is maintained in metastatic foci and in …
Learn More

LGH 2023-36: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

99 years and younger
All genders
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
Learn More

LGH 2019-29: DUO-O

99 years and younger
All genders
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Learn More
341 - 350 of 930